Canerpaturev - Takara Bio

Drug Profile

Canerpaturev - Takara Bio

Alternative Names: HF10; Msc 2; TBI-1401

Latest Information Update: 03 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ms Science; Nagoya University
  • Developer Takara Bio; University of Utah
  • Class Antineoplastics; Oncolytic viruses
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Malignant melanoma
  • Phase I Pancreatic cancer
  • No development reported Head and neck cancer; Solid tumours

Most Recent Events

  • 05 Jun 2018 Takara Bio completes a phase II trial in Malignant melanoma (Late-stage disease, Inoperable/unresectable, Metastatic disease, Combination therapy) in USA (Intratumoural)
  • 13 Dec 2017 Phase-II clinical trials in Malignant melanoma (Combination therapy, Second-line therapy or greater, Neoadjuvant therapy, Late-stage disease, Metastatic disease) in USA (Intratumoural) (NCT03259425)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Head-and-neck-cancer in USA (Intratumoural, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top